BioNexus Gene Lab financials
$1.27−2.31%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $7.4M | $9.5M | $9.8M |
| Gross profit | $1.1M | $1.3M | $1.3M |
| Gross margin | 14.6% | 13.6% | 13.6% |
| Operating income | -$3.3M | -$3.6M | -$3.1M |
| Net income | -$3.0M | -$1.6M | -$2.6M |
| Net margin | −40.2% | −16.8% | −26.9% |
| Diluted EPS | $-1.61 | $-0.90 | $-0.17 |
| EBITDA | -$3.2M | -$3.5M | -$3.0M |
| Operating cash flow | -$1.8M | -$2.1M | -$1.8M |
| Free cash flow | -$1.9M | -$2.3M | -$2.3M |
| Diluted shares | 1.9M | 1.8M | 15.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $2.4M | $1.6M | $2.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 |
| Total assets | $9.3M | $10.4M | $11.4M |
| Total liabilities | $637.9K | $2.1M | $1.7M |
| Shareholders' equity | $8.6M | $8.3M | $9.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology